Recode Ventures

ActiveVenture Capital

Updated: Jan 6, 2026 ·

About

Recode Ventures is the world's first AI healthcare venture capital firm, investing in seed and series A founders who are transforming healthcare through technology.

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Sep 1, 2025	Fiveonefour	$17.0M Series A	—	Dimension Capital, Molten Ventures, Passion Capital, Seedcamp, SuperSeed, Mads Jensen, Paul Forster
Jan 1, 2024	Genomics	$45.0M Series C	—	ARCH Venture Partners, Ameena El-Bibany, Foresite Capital, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Molten Ventures, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky
Nov 1, 2023	qomodo	$37.0M Seed	—	Aglae Ventures, Adeyemi Ajao, Dimension Capital, Double Prime LLP, Frontline Ventures, Molten Ventures, Passion Capital, Picus Capital, Primo Ventures, Seedcamp, Stride VC, SuperSeed, Alexandre Prot, Alexis Bonillo, Benjamin Chemla, Didier Valet, Luca Ascani, Mads Jensen, Massimo Ciociola, Nicolas Julia, Pascal Gauthier, Paul Forster, Ron Pragides, Sebastien Borget, Tony Jamous
Sep 1, 2023	Rollstack	$2.0M Seed	—	AirAngels, AngelList, Dimension Capital, Khosla Ventures, Molten Ventures, Passion Capital, Seedcamp, Soma Capital, SuperSeed, UpHonest Capital, Balaji Srinivasan, Gokul Rajaram, Mads Jensen, Matteo Franceschetti, Vishal Rao
Aug 1, 2023	Viome	$87.0M Series C	—	Alliance of Angels, Bold Capital Partners, Alan Cohen, Khosla Ventures, SOSV, Marc Benioff
Aug 1, 2023	Verisian	$1.0M Seed	—	14Peaks Capital, Bowery Capital, Dimension Capital, Molten Ventures, Passion Capital, Rebel Fund, #SecretFund, Seedcamp, SuperSeed, Allen Gannett, Charles Delingpole, Christian Reber, Johnny Boufarhat, Luca Ascani, Mads Jensen, Nick Caldwell, Paul Forster, William Tunstall-Pedoe, Youcef Es-skouri
Feb 1, 2023	evonetix	$24.0M Series B	—	Matt Ocko, Dimension Capital, First Round Capital, Foresite Capital, Krishna Yeshwant, IA Ventures, K9 Ventures, Lux Capital, Northpond Ventures, Uncork Capital, UpHonest Capital, Y Combinator, Nat Goldhaber
Oct 1, 2022	Viome	$67.0M Series C	—	Bold Capital Partners, Alan Cohen, Khosla Ventures, SOSV
Jul 1, 2021	Dutch	$5.0M Seed	—	Bling Capital, Collaborative Seed & Growth Partners, Forerunner Ventures, Founders Fund, High Alpha, Kleiner Perkins, Microsoft, Optum Ventures, Revolution, Threshold Ventures, Tiger Global Management, Georges Harik, Steph Korey, Vince Monical, Yann LeCun
Jul 1, 2021	Genvid Technologies	$110.0M Series C	—	AIX Ventures, Atreides Management, Big Sky Health, BITKRAFT Ventures, C2 Investment, Chemistry VC, Matt Ocko, Dell Technologies Capital, Dimension Capital, First Round Capital, Galaxy Digital, Galaxy Interactive, Gutter Capital, IA Ventures, Imagination Capital, LaunchPad, LightShed Ventures, Lowercarbon Capital, Lux Capital, Moonshots Capital, Nexus Venture Partners, O'Shaughnessy Ventures, Anandamoy Roychowdhary, Shailendra Singh, Positive Sum VC, Quiet Capital, Redpoint Ventures, Science, Howard Lindzon, Jarrod Dicker, Tenaya Capital, UpHonest Capital, Vast Ventures, WGI Group, Y Combinator, Diego Berdakin, Don Dodge, Joe Proto, Josh Elman, Kevin Lin, Loic Le Meur, Mark Pincus
Jul 1, 2021	Pivot Bio	$430.0M Series D	—	Breakthrough Energy Ventures, Calibrate Ventures, DCVC (Data Collective), Dimension Capital, Giant Ventures, Hyperplane Venture Capital, IA Ventures, Lux Capital, Scale Venture Partners, Tekfen Ventures, UpHonest Capital, Y Combinator
Jun 1, 2021	Strateos	$56.0M Series B	—	8VC, Altaclub VC, ARCH Venture Partners, Bling Capital, Brand New Matter, DCVC (Data Collective), Kima Ventures, LombardStreet Ventures, Lux Capital, MetaProp Ventures, Scott Gottlieb, Picus Capital, #SecretFund, SeedInvest, Georges Harik, Jean Charles Samuelian, Keith Masback, Rob Bernshteyn, Roxanne Varza, Vince Monical, Yann LeCun
Feb 1, 2021	Genomics	$30.0M Venture Round	—	ARCH Venture Partners, Ameena El-Bibany, Foresite Capital, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Molten Ventures, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky
Jul 1, 2020	Caption Health	$53.0M Series B	—	305 Ventures, Arrive, Bling Capital, Bold Capital Partners, Curie.Bio, Alan Cohen, Founders Fund, Great Oaks Venture Capital, Khosla Ventures, LGF, Operator Partners, Ribbit Capital, Sequoia Capital, Streamlined Ventures, Adrian Aoun, Samvit Ramadurgam, Sohail Prasad, Steve Chen
Jun 1, 2020	Proprio	$23.0M Series A	—	Bold Capital Partners, Breakthrough Energy Ventures, John Hamer, Matt Ocko, DCVC (Data Collective), Genoa Ventures, Tekfen Ventures
Apr 1, 2020	Pivot Bio	$100.0M Series C	—	Breakthrough Energy Ventures, Calibrate Ventures, DCVC (Data Collective), Dimension Capital, Giant Ventures, Karim Faris, Hyperplane Venture Capital, IA Ventures, Kleiner Perkins, Lux Capital, Scale Venture Partners, Tekfen Ventures, UpHonest Capital, Y Combinator
Mar 1, 2020	evonetix	$30.0M Series B	—	ACME Capital, Balderton Capital, Band of Angels, Matt Ocko, Dimension Capital, First Round Capital, Foresite Capital, Krishna Yeshwant, IA Ventures, K9 Ventures, Lux Capital, MassMutual Ventures, Molten Ventures, Northpond Ventures, Scalebridge Capital, Uncork Capital, UpHonest Capital, Y Combinator, Esther Dyson, Nat Goldhaber, Richard De Silva
Jul 1, 2019	Strateos	$17.0M Venture Round	—	8VC, ARCH Venture Partners, Bling Capital, Kima Ventures, Lux Capital, Scott Gottlieb, Picus Capital, #SecretFund, Georges Harik, Jean Charles Samuelian, Roxanne Varza, Vince Monical, Yann LeCun
Feb 1, 2019	Antescofo	$5.0M Seed	—	Bling Capital, Georges Harik, Vince Monical
Jan 1, 2018	evonetix	$12.0M Series A	—	ACME Capital, Artis Ventures (AV), Balderton Capital, Band of Angels, Matt Ocko, Dimension Capital, IA Ventures, Lux Capital, MassMutual Ventures, Molten Ventures, Scalebridge Capital, UpHonest Capital, Y Combinator, Esther Dyson, Richard De Silva
Feb 1, 2017	Gamalon	$4.0M Seed	—	11.2 Capital, AME Cloud Ventures, Atlas Venture, Autotech Ventures, Bessemer Venture Partners, Bling Capital, Cota Capital, Expa, Flex Capital, GFT Ventures, Greylock, Hardware Club, Long Journey Ventures, M34 Capital, NEO, Next47, Pareto Holdings, Playground Global, Point72 Ventures, Sherpalo Ventures, Susa Ventures, SV Angel, UpHonest Capital, Walden International, Adam Foroughi, Hadi Partovi, Jerry Fiddler, John Hennessy, Ricardo Marino, Vince Monical, Yann LeCun
Dec 1, 2016	Caption Health	$6.0M Series A	—	305 Ventures, Arrive, Bling Capital, Bold Capital Partners, Curie.Bio, Alan Cohen, Founders Fund, Great Oaks Venture Capital, Khosla Ventures, LGF, Marathon Venture Capital, Operator Partners, Pioneer Fund, Ribbit Capital, Sequoia Capital, Streamlined Ventures, Adrian Aoun, Samvit Ramadurgam, Sohail Prasad, Steve Chen
Nov 1, 2016	Strateos	$13.0M Venture Round	—	Altaclub VC, Bling Capital, Brand New Matter, DCVC (Data Collective), LombardStreet Ventures, MetaProp Ventures, SeedInvest, Georges Harik, Keith Masback, Rob Bernshteyn, Vince Monical, Yann LeCun
Sep 1, 2016	Gamalon	$4.0M Venture Round	—	11.2 Capital, AME Cloud Ventures, Atlas Venture, Autotech Ventures, Bessemer Venture Partners, Bling Capital, Cota Capital, Flex Capital, GFT Ventures, Greylock, Hardware Club, M34 Capital, NEO, Next47, Pareto Holdings, Playground Global, Point72 Ventures, Sherpalo Ventures, Susa Ventures, SV Angel, UpHonest Capital, Walden International, Adam Foroughi, Hadi Partovi, Jerry Fiddler, Ricardo Marino, Vince Monical, Yann LeCun
Mar 1, 2016	Pivot Bio	$16.0M Series A	—	Amplify Partners, Atlas Venture, Audrey Capital, Avalon Ventures, Celesta, DCVC (Data Collective), Dell Technologies Capital, Dimension Capital, Fuel Capital, Genoa Ventures, Heavybit, IA Ventures, IDG Ventures, Lux Capital, Alexander Rosen, Gil Penchina, UpHonest Capital, Vertex Ventures, Y Combinator, Alex Payne, Eric Ries, Jeremy LaTrasse, Kyle York, Mark Williamson

Financial History

Total Raised

N/A

Valuation

N/A

Leadership Team

Key people at Recode Ventures.

Armen Vidian

Managing Partner

Leadership Team

Key people at Recode Ventures.

Armen Vidian

Managing Partner

Deep Dive

High-Level Overview

Recode Ventures is a venture capital firm specializing in early-stage investments at the intersection of healthcare and artificial intelligence (AI). Its mission is to back tech-native founders who are leveraging AI and emerging technologies to revolutionize healthcare, aiming to treat and cure diseases that affect billions globally. The firm primarily provides seed and Series A funding to startups innovating in areas such as gene targeting, antibody development, cell therapy, cardiology, and surgical guidance. By combining strategic investments with mentorship and industry expertise, Recode Ventures plays a pivotal role in advancing medical innovation and reshaping healthcare delivery across the US and Europe[1][2][5].

Origin Story

Founded in 2022, Recode Ventures emerged from the recognition by its founders—who include clinicians, scientists, engineers, and entrepreneurs—of the urgent need to bridge the gap between cutting-edge research and real-world healthcare applications. The founding partners bring decades of experience in life sciences and deep tech venture environments, particularly from institutions like the University of Oxford and Imperial College London. This background shaped their focus on supporting AI-driven healthcare startups with robust translational pathways. The firm operates from San Francisco and London, reflecting its global outlook and commitment to fostering innovation on both continents[1][4][5].

Core Differentiators

Specialized Focus: The world’s first venture capital firm dedicated exclusively to healthcare AI companies, providing deep domain expertise.
Founders’ Empathy: Comprised of founders, doctors, engineers, and scientists, the team intimately understands the challenges faced by portfolio companies.
Investment Model: Early-stage focus (seed and Series A) with a hands-on approach combining capital, mentorship, and strategic guidance.
Network Strength: Strong connections with leading scientific and medical institutions, as well as partnerships like the one with Eli Lilly for the Recode Edge program supporting early-stage AI healthcare startups.
Track Record: Portfolio includes pioneering ventures advancing gene targeting, antibody development, cell therapy, cardiology, and surgical guidance.
Operating Support: Provides founders with battle-tested expertise spanning clinical medicine, product development, and launch strategies[1][3][5][6].

Role in the Broader Tech Landscape

Recode Ventures rides the wave of convergence between AI and healthcare, a trend accelerated by advances in computational power (Moore’s Law) and the maturation of life sciences technologies. This timing is critical as AI platforms increasingly enable breakthroughs in diagnostics, therapeutics, and personalized medicine. By focusing on AI-first healthcare startups, Recode Ventures influences the broader ecosystem by accelerating the translation of scientific innovation into scalable healthcare solutions. Its partnership with established pharmaceutical companies like Eli Lilly further integrates venture innovation with industry R&D, fostering a collaborative environment for transformative healthcare technologies[1][3][6].

Quick Take & Future Outlook

Looking ahead, Recode Ventures is positioned to deepen its impact by expanding its portfolio of AI-driven healthcare startups and scaling programs like Recode Edge to nurture early-stage innovators globally. As AI continues to evolve and integrate with other emerging technologies, the firm’s specialized expertise and network will be crucial in identifying and supporting ventures that can deliver significant clinical and commercial breakthroughs. Their influence is likely to grow as healthcare increasingly embraces AI for disease treatment, prevention, and management, potentially reshaping global health outcomes and the venture capital landscape in this sector[3][6].

Sources

High-Level Overview

Origin Story

Core Differentiators

Specialized Focus: The world’s first venture capital firm dedicated exclusively to healthcare AI companies, providing deep domain expertise.
Founders’ Empathy: Comprised of founders, doctors, engineers, and scientists, the team intimately understands the challenges faced by portfolio companies.
Investment Model: Early-stage focus (seed and Series A) with a hands-on approach combining capital, mentorship, and strategic guidance.
Network Strength: Strong connections with leading scientific and medical institutions, as well as partnerships like the one with Eli Lilly for the Recode Edge program supporting early-stage AI healthcare startups.
Track Record: Portfolio includes pioneering ventures advancing gene targeting, antibody development, cell therapy, cardiology, and surgical guidance.
Operating Support: Provides founders with battle-tested expertise spanning clinical medicine, product development, and launch strategies[1][3][5][6].